SMAD3 and breast cancer: TGF-β or EGF on HER2-overexpressed breast cancer cells can induce SMAD3 phosphorylation, and CEACAM6 expression level is upregulated after treatment, but this correlation is not obvious in HER2-negative breast cancer cells.